SFKs inhibit the activity of the retinoic acid receptor alpha (RARα [27], and SFK inhibitors (PP2, dasatinib) enhanced ATRA-mediated cellular differentiation in an AML cell line and primary blasts via Lyn inhibition-mediated activation of RAF-1/MEK/ERK [28,29,30,31]. The gene discussed is RARA; the disease is acute myeloid leukemia.